Edmonton's Royal Alexandra Hospital and University of Alberta Hospital manage Hepatitis C patients across Northern Alberta — including patients from Edmonton's significant Indigenous communities and those with histories of injection drug use who remain underserved by provincial HCV programmes. Resof L provides affordable Ledipasvir+Sofosbuvir cure at a fraction of brand pricing for Edmonton patients facing access gaps.
Alberta Health covers HCV direct-acting antivirals through the Pharmaceutical Benefit Programme, but eligibility restrictions and fibrosis staging requirements have historically limited access for some patients. Generic Resof L provides an important supplementary access pathway ensuring no patient misses curative treatment due to administrative barriers.
Visit medshopy.com or WhatsApp +91 82650 41513.
Alberta Health covers HCV direct-acting antivirals through the Pharmaceutical Benefit Programme, but eligibility restrictions and fibrosis staging requirements have historically limited access for some patients. Generic Resof L provides an important supplementary access pathway ensuring no patient misses curative treatment due to administrative barriers.
Visit medshopy.com or WhatsApp +91 82650 41513.
Why were Hepatitis C treatments historically restricted based on liver fibrosis stage, and has this changed?Early direct-acting antiviral HCV programmes restricted treatment to patients with more advanced liver fibrosis (stage F2 or higher) primarily due to cost — brand DAA courses cost $40,000-80,000+ and payers sought to prioritise those at highest risk of imminent liver failure and death. This approach was criticised as ethically problematic, since curing Hepatitis C at any fibrosis stage prevents future progression, eliminates the source of ongoing transmission, and is equally effective regardless of disease stage. As generic competition reduced costs dramatically, most jurisdictions including Canadian provinces have progressively removed fibrosis-based restrictions and now offer HCV treatment to all patients regardless of liver stage — a policy change that accelerated national elimination goals significantly.